These data demonstrate that by exerting FXR-antagonistic effects, UDCA treatment in NAFLD patients strongly impacts on cholesterol and BA synthesis and induces neutral lipid accumulation in both liver and vWAT. The gene discussed is NR1H4; the disease is metabolic dysfunction-associated steatotic liver disease.